Enormous investments in AIDS related research and in public education have not been able to stem the worldwide pandemic. The consequences of this are most dire in developing parts of the world where transmission rates continue to increase at alarming rates, with women being particularly vulnerable to infection. Development of a protective vaccine is not likely in the short-term, thus the availability of alternative means of HIV infection prevention is critical. Effective microbicides administered vaginally may be an important means of prevention that have the further advantage of empowering women who are unable to negotiate condom use with the ability to protect themselves. This Program Project application is responsive to the stated objectives of announcement PA- 01-075; specifically, to advance development and optimization of lead topical microbicide candidates and to advance these microbicide candidates into pilot clinical studies. Biosyn, Inc. has assembled an outstanding team of scientists and drug development experts to specifically develop and advance cyanovirin-N (CV-N) as an anti-HIV topical microbicide. CV-N is one of the most interesting anti-HIV compounds available for microbicide development. Three separate research projects within the program will focus on: the production of CV-N protein in recombinant expression systems; the study of CVN formulation deployment in vitro and in vivo; and the feasibility of using CV-N in combination with other microbicide candidates as determined in an ex vivo system. These research projects will be supported by three cores which will be responsible for: administration and drug development; formulation, development; and virology testing. The iterative research and development efforts of these projects and cores will be a powerful means of rapidly and effectively advancing CV-N as an anti-HIV microbicide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI051650-02
Application #
6663747
Study Section
Special Emphasis Panel (ZAI1-VSG-A (J1))
Program Officer
Turpin, Jim A
Project Start
2002-09-30
Project End
2007-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
2
Fiscal Year
2003
Total Cost
$2,060,666
Indirect Cost
Name
Biosyn, Inc.
Department
Type
DUNS #
City
Huntingdon Valley
State
PA
Country
United States
Zip Code
19006
Su, H Irene; Schreiber, Courtney A; Fay, Courtney et al. (2011) Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception 84:525-32
Barnhart, Kurt; Kulp, Jennifer L; Rosen, Mark et al. (2009) A randomized trial to determine the distribution of four topical gel formulations in the human vagina. Contraception 79:297-303
Owen, Derek H; Peters, Jennifer J; Kieweg, Sarah L et al. (2007) Biophysical analysis of prototype microbicidal gels. J Pharm Sci 96:661-9
McFadden, Karyn; Cocklin, Simon; Gopi, Hosahudya et al. (2007) A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 67:617-29
Tien, Deborah; Schnaare, Roger L; Kang, Feirong et al. (2005) In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21:845-53
Colleluori, Diana M; Tien, Deborah; Kang, Feirong et al. (2005) Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Protein Expr Purif 39:229-36